Jim Mackey stated, 'We are really worried about this. We've already had a couple of supply shocks in the last 12 to 18 months of key supplies.' He emphasized the importance of contingency planning due to the UK's reliance on imported medicines.
Each day, they pore over reams of data about how the virus is evolving worldwide, how well last year's shot performed, and which strains might be easiest to mass produce for a vaccine. The meeting, convened by the World Health Organization twice a year, is a critical moment for the WHO's Global Influenza Surveillance and Response System.
At the end of January, Washington, DC, saw an extremely unusual event. The MAHA Institute, which was set up to advocate for some of the most profoundly unscientific ideas of our time, hosted leaders of the best-funded scientific organization on the planet, the National Institutes of Health. Instead of a hostile reception, however, Jay Bhattacharya, the head of the NIH, was greeted as a hero by the audience, receiving a partial standing ovation when he rose to speak.
If you're based in the United States, you've probably gotten used to government bodies issuing nationwide alerts - including ones that relate to public health. These have, historically, been good ways for health-conscious people to know what to look out for and for regional public health experts to develop strategies to help keep potential outbreaks contained.Unfortunately, now both individuals and institutions are reckoning with a big question: what to do when those warnings are much smaller in number?
Monday's sweeping decision, which advances the agenda of Trump-appointed Secretary of Health Robert F Kennedy Jr, removes the recommendation for rotavirus, influenza, meningococcal disease and hepatitis A vaccines for children. list of 3 itemsend of list It comes as US vaccination rates have been slipping, and the rates of diseases that can be protected against with vaccines, such as measles and whooping cough, are rising across the country, according to government data.
the research would have followed 14,000 infants in the West African nation of Guinea-Bissau. The problem? Only 7,000 of those newborns would have received an urgently needed hepatitis B vaccine, in order to compare the two groups. On top of the flagrant ethics violations, the total cost of the research would have exceeded the cost to pay for "over a decade's worth of Hepatitis B vaccine birth doses [for everyone] in Guinea-Bissau."
